Thermo Opens New Site in China

Thermo Fisher Scientific (Waltham, Massachusetts, USA) is opening a site in Hangzhou, China, as part of its global effort to help companies provide therapies to patients faster. The 80,000-square‑metre current Good Manufacturing Practices (cGMP) facility will offer integrated clinical and commercial drug substance and drug product capabilities, including process development, cell line development, biologics drug substance manufacturing, and sterile fill-finish.

“Hangzhou is a strategic addition to our global pharma services network and the latest example of our commitment to meeting customer demands globally,” said Mike Shafer, senior vice president and president, pharma services. “We continue to invest in capabilities to support the manufacturing needs of our customers, enabling them to serve more patients throughout the world.”

“Thermo Fisher has been in China for 40 years, serving this market through its bioproduction, clinical research and pharma services businesses,” said Hann Pang, president, Thermo Fisher China. “Committed to our ‘in China, for China’ localization strategy, we are enhancing our workflow capabilities to fully support pharmaceutical and biotechnology companies in China and worldwide in helping more local innovations go global.”

For more information, please visit: www.thermofisher.com